[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 15, Issue 4 (Winter 2018) ::
Sci J Iran Blood Transfus Organ 2018, 15(4): 257-264 Back to browse issues page
Cost-utility of treatment of the patients with Thalassemia Major in Iran
S. Emamgholipour Dr., B. Ahmadi Dr., A.H. Rajabi Dr., A. Azarkeivan Dr., M. Ebrahimi Dr., F. Esmaeilzadeh Dr.
Abstract:   (1344 Views)
Background and Objectives
Thalassemia major is an autosomal recessive disease with serious morbidity, mortality and pathology. Due to today’s therapeutic advances, the life expectancy of thalassemia patients has significantly increased. As a result, thalassemia patients need lifelong care, but caring for patients with thalassemia causes a lot of costs. Therefore, being aware of the costs and effectiveness of the treatments is essential for controlling the costs and providing effective treatments.
Materials and Methods
In this cross-sectional descriptive study, a bottom-up method was used to estimate the treatment costs for thalassemia patients and all the costs were estimated over a one-year period (2015). The number of QALYs created by treatment was also extracted using the EQ5D questionnaire, and eventually, the Markov model was used to calculate the costs and effectiveness for patients’ longevity.
Treatment for any patients with thalassemia major costs $ 8,321.8 per year. Applying a 3% discount rate, we estimated that each patient lifelong treatment costs $ 147,098.4, which would results in 11.8 QALYs. Hence, the cost per QALY would be $ 12,466,0.
Treating the patients with thalassemia major, despite its cost effectiveness, might cost a lot so that the treatment of the patients in the fourth decade of their lives may even reach the cost-effectiveness threshold. Therefore, increasing the costs in the field of patient screening and prevention of the birth of patients with thalassemia major seems to be useful.
Keywords: Key words: Cost-Benefit Analysis, beta-Thalassemia, Iran
Full-Text [PDF 318 kb]   (308 Downloads) |   |   Full-Text (HTML)  (253 Views)  
Type of Study: Research | Subject: Thalasemia
Published: 2019/01/5
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Emamgholipour S, Ahmadi B, Rajabi A, Azarkeivan A, Ebrahimi M, Esmaeilzadeh F. Cost-utility of treatment of the patients with Thalassemia Major in Iran. Sci J Iran Blood Transfus Organ. 2018; 15 (4) :257-264
URL: http://bloodjournal.ir/article-1-1193-en.html

Volume 15, Issue 4 (Winter 2018) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.09 seconds with 33 queries by YEKTAWEB 4030